48.36
0.32 (0.67%)
| Penutupan Terdahulu | 48.04 |
| Buka | 48.00 |
| Jumlah Dagangan | 303,183 |
| Purata Dagangan (3B) | 737,141 |
| Modal Pasaran | 3,437,163,520 |
| Harga / Buku (P/B) | 2.36 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| EPS Cair (TTM) | -2.58 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.92% |
| Nisbah Semasa (MRQ) | 23.29 |
| Aliran Tunai Operasi (OCF TTM) | -134.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -80.30 M |
| Pulangan Atas Aset (ROA TTM) | -17.24% |
| Pulangan Atas Ekuiti (ROE TTM) | -22.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Structure Therapeutics Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 3.08% |
| % Dimiliki oleh Institusi | 101.62% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Avoro Capital Advisors Llc | 31 Mar 2026 | 6,555,555 |
| Casdin Capital, Llc | 31 Mar 2026 | 1,175,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jun 2026 | CNBC | Drugmakers race to find a place in the next wave of obesity drugs |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |